Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2023.1245
Abstract: Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD) recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long-acting β-agonists (LABAs) over inhalers containing inhaled corticosteroids (ICSs) and LABAs. However, data from randomized clinical trials comparing… read more here.
Keywords: laba therapy; ics laba; chronic obstructive; lama laba ... See more keywords
LA inhalers for COPD: perceptions/reality of ABCD GOLD tool use
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Community Hospital Internal Medicine Perspectives"
DOI: 10.1080/20009666.2020.1786915
Abstract: ABSTRACT Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) created an ABCD tool to assess staging and severity of COPD subgroups that respond to LAMA or LABA with improved quality of life and… read more here.
Keywords: use; tool; copd; gold ... See more keywords
Dual bronchodilation for the treatment of COPD: From bench to bedside
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15390
Abstract: Because there is a solid pharmacological rationale based on positive interactions between long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) for their ability to relax human airway smooth muscle in vitro alongside several randomised… read more here.
Keywords: bronchodilation; copd; laba fdcs; lama laba ... See more keywords
P242 Demographics and clinical characteristics of patients with COPD utilizing LAMA/LABA fixed-dose combination therapy: a U.S. database study
Sign Up to like & getrecommendations! Published in 2018 at "Thorax"
DOI: 10.1136/thorax-2018-212555.399
Abstract: Introduction and objectives To characterize patients with chronic obstructive pulmonary disease (COPD) who were prescribed long-acting muscarinic antagonist/long-acting &bgr;2-agonist (LAMA/LABA) fixed-dose combination (FDC) therapy in real-world US-based clinical practice. Methods This retrospective cohort study of… read more here.
Keywords: therapy; index; laba fdc; lama laba ... See more keywords
P247 Umeclidinium/vilanterol (UMEC/VI) versus mono-bronchodilator therapy in steroid-free GOLD B patients with chronic obstructive pulmonary disease (COPD): the EMAX trial
Sign Up to like & getrecommendations! Published in 2018 at "Thorax"
DOI: 10.1136/thorax-2018-212555.403
Abstract: Introduction Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) combination therapy is more effective than monotherapies for improving lung function, breathlessness and health status, in patients with moderate-to-severe COPD (Oba et al. Thorax 2016:71;15–25). Current Global initiative for… read more here.
Keywords: gold patients; copd; versus; gold ... See more keywords
Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2018.pa4385
Abstract: Rationale: Current GOLD strategy document positions both combination regimens of inhaled corticosteroid plus a long-acting β2-agonist [i.e. ICS/LABA] and long-acting muscarinic antagonist plus LABA [i.e. LAMA/LABA] for symptomatic patients with recurrent exacerbations. Methods: The InforMing… read more here.
Keywords: treatment; ics laba; lung function; lama laba ... See more keywords
Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Research"
DOI: 10.1186/s12931-020-01540-8
Abstract: Background Only few randomized controlled trials (RCTs) for head-to-head comparison have been conducted between various combinations of long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs). Our study was conducted to compare acute exacerbation and all-cause… read more here.
Keywords: mortality among; network; among lama; laba combinations ... See more keywords
Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "PLoS Medicine"
DOI: 10.1371/journal.pmed.1002958
Abstract: Background Although exacerbation and mortality are the most important clinical outcomes of stable chronic obstructive pulmonary disease (COPD), the drug classes that are the most efficacious in reducing exacerbation and mortality among all possible inhaled… read more here.
Keywords: chronic obstructive; obstructive pulmonary; mortality; ics lama ... See more keywords